Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine in Hepatopulmonary Syndrome
NCT03600870Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of midodrine in hepatopulmonary syndrome (HPS), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 6 months. Started Aug 2018; status: completed.
02
Drugs
midodrine
03
Conditions
hepatopulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT03600870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600870.